Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Antiobesity agent from Neurogen/Pfizer advances to multiple-dose trials

Feb. 6, 1997

Impotence Rx expected to enter phase II this year

Feb. 5, 1997

FDA panel to review Carticel service

Feb. 5, 1997

GelMed receives patent coverage for new use of polymers

Feb. 4, 1997

Novel diabetes treatments reported by Shaman

Feb. 4, 1997

Pfizer claims glycogen phosphorylase inhibitors

Feb. 4, 1997

Successful completion of phase I trial of aerosolized osteoporosis product

Feb. 3, 1997

Inhale/Lilly collaborate on pulmonary delivery of osteoporosis Rx

Feb. 3, 1997

Hypoglycemic/hypolipidemic agents from Sumitomo Metal

Feb. 3, 1997

Japanese researchers describe compounds for lipoprotein disorders

Feb. 3, 1997

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
New schizophrenia targets challenge trial design
BioWorld
The search for better schizophrenia therapies is moving beyond dopamine toward a growing number of experimental targets. According to researchers, the repeated...
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
News in brief
BioWorld Asia
BioWorld Asia briefs for July 28, 2026
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...